Morgan Stanley
MDNA

Morgan Stanley’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Morgan Stanley’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,800
Closed -$531 – 8024
2023
Q3 		$531 Hold
1,800
– – ﹤0.01% 7300
2023
Q2 		$867 Hold
1,800
– – ﹤0.01% 7318
2023
Q1 		$1.13K Hold
1,800
– – ﹤0.01% 7335
2022
Q4 		$824 Hold
1,800
– – ﹤0.01% 7494
2022
Q3 		$1K Sell
1,800
-200,000
-99% -$226K ﹤0.01% 7639
2022
Q2 		$234K Buy
201,800
+197,981
+5,184% +$212K ﹤0.01% 5818
2022
Q1 		$5K Sell
3,819
-3,521
-48% -$5.47K ﹤0.01% 7603
2021
Q4 		$12K Sell
7,340
-31,265
-81% -$64.8K ﹤0.01% 7426
2021
Q3 		$107K Sell
38,605
-25,000
-39% -$61.9K ﹤0.01% 6335
2021
Q2 		$192K Sell
63,605
-3,993
-6% -$14.8K ﹤0.01% 6040
2021
Q1 		$276K Buy
67,598
+57,868
+595% +$236K ﹤0.01% 5474
2020
Q4 		$45K Buy
9,730
+8,430
+648% +$34K ﹤0.01% 6192
2020
Q3 		$5K Buy
+1,300
New +$5.23K ﹤0.01% 6456

Other funds holding MDNA

RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
NDSI
Newman Dignan & Sheerar Inc Providence, Rhode Island $523M AUM 26.16% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley's MDNA Position: Q4 2023 in Review

Morgan Stanley sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2023, closing a stake of 1,800 shares — an estimated $531 sold.

Morgan Stanley first reported a position in MDNA in Q3 2020 and held it in 13 quarters. The position peaked at $276K in Q1 2021. 3 funds tracked by Wall St. Rank hold MDNA as of Q4 2023.

  • Morgan Stanley reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 1,800 Medicenna Therapeutics Corp. Common Shares shares in Q4 2023, an estimated $531.
  • Morgan Stanley first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 13 quarters.
  • Morgan Stanley's Medicenna Therapeutics Corp. Common Shares position peaked at $276K in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.